Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lack of CD8 + T cell effector differentiation during priming mediates checkpoint blockade resistance in non–small cell lung cancer
Brendan Horton, Duncan M. Morgan, Noor Momin, et al.
Science Immunology (2021) Vol. 6, Iss. 64
Open Access | Times Cited: 97

Showing 1-25 of 97 citing articles:

A neutrophil response linked to tumor control in immunotherapy
Jeremy Gungabeesoon, Nicolas A. Gort-Freitas, Máté Kiss, et al.
Cell (2023) Vol. 186, Iss. 7, pp. 1448-1464.e20
Closed Access | Times Cited: 202
CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor
Nataliya Prokhnevska, Maria A. Cardenas, Rajesh M. Valanparambil, et al.
Immunity (2022) Vol. 56, Iss. 1, pp. 107-124.e5
Open Access | Times Cited: 190
The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients
Mirco Friedrich, Paola Neri, Niklas Kehl, et al.
Cancer Cell (2023) Vol. 41, Iss. 4, pp. 711-725.e6
Open Access | Times Cited: 121
Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy
Kailin Yang, Ahmed Halima, Timothy A. Chan
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 9, pp. 604-623
Closed Access | Times Cited: 113
Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer
Maria Zagorulya, Leon Yim, Duncan M. Morgan, et al.
Immunity (2023) Vol. 56, Iss. 2, pp. 386-405.e10
Open Access | Times Cited: 86
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
Itziar Otano, Álvaro C. Ucero, Jon Zugazagoitia, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 3, pp. 143-159
Closed Access | Times Cited: 84
An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis
Nelson M. LaMarche, Samarth Hegde, Matthew D. Park, et al.
Nature (2023) Vol. 625, Iss. 7993, pp. 166-174
Open Access | Times Cited: 81
Stem-like exhausted and memory CD8+ T cells in cancer
Thomas Gebhardt, Simone L. Park, Ian A. Parish
Nature reviews. Cancer (2023) Vol. 23, Iss. 11, pp. 780-798
Closed Access | Times Cited: 70
From structural design to delivery: mRNA therapeutics for cancer immunotherapy
Feng Zhou, Lujia Huang, Shiqin Li, et al.
Exploration (2023) Vol. 4, Iss. 2
Open Access | Times Cited: 50
Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges
Yuchu Xiang, Xudong Liu, Yifan Wang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 23
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer
Ray Pillai, Sarah E. LeBoeuf, Yuan Hao, et al.
Science Advances (2024) Vol. 10, Iss. 13
Open Access | Times Cited: 20
Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer
Minae An, Arnav Mehta, Byung‐Hoon Min, et al.
Cancer Discovery (2024) Vol. 14, Iss. 5, pp. 766-785
Open Access | Times Cited: 18
Cancer immune evasion, immunoediting and intratumour heterogeneity
Malte Roerden, Stefani Spranger
Nature reviews. Immunology (2025)
Closed Access | Times Cited: 7
Knowns and Unknowns about CAR-T Cell Dysfunction
Aleksei Titov, Yaroslav Kaminskiy, Irina Ganeeva, et al.
Cancers (2022) Vol. 14, Iss. 4, pp. 1078-1078
Open Access | Times Cited: 39
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer
Inês Mota, Enrico Patrucco, Cristina Mastini, et al.
Nature Cancer (2023) Vol. 4, Iss. 7, pp. 1016-1035
Closed Access | Times Cited: 27
Mechanisms of CD8+ T cell exclusion and dysfunction in cancer resistance to anti-PD-(L)1
Keywan Mortezaee, Jamal Majidpoor
Biomedicine & Pharmacotherapy (2023) Vol. 163, pp. 114824-114824
Open Access | Times Cited: 25
Dendritic cell-targeted therapy expands CD8 T cell responses to bona-fide neoantigens in lung tumors
Lucía López, Luciano Gastón Morosi, Federica La Terza, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 15
Lymphatic vessels in the age of cancer immunotherapy
Triantafyllia Karakousi, Tenny Mudianto, Amanda W. Lund
Nature reviews. Cancer (2024) Vol. 24, Iss. 6, pp. 363-381
Closed Access | Times Cited: 14
The activity and immune dynamics of PD-1 inhibition on high-risk pulmonary ground glass opacity lesions: insights from a single-arm, phase II trial
Bo Cheng, Caichen Li, Jianfu Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 8
Expansion of tumor-reactive CD8 + T cell clonotypes occurs in the spleen in response to immune checkpoint blockade
Duncan M. Morgan, Brendan Horton, Vidit Bhandarkar, et al.
Science Immunology (2024) Vol. 9, Iss. 99
Closed Access | Times Cited: 8
Cellular Dynamics of Tumor Microenvironment Driving Immunotherapy Resistance in Non-Small-Cell Lung Carcinoma
Shujie Huang, Jeff Yat‐Fai Chung, Chunjie Li, et al.
Cancer Letters (2024), pp. 217272-217272
Closed Access | Times Cited: 8
Architects of immunity: How dendritic cells shape CD8 + T cell fate in cancer
Vidit Bhandarkar, Teresa Dinter, Stefani Spranger
Science Immunology (2025) Vol. 10, Iss. 103
Closed Access | Times Cited: 1
CXCL5-mediated accumulation of mature neutrophils in lung cancer tissues impairs the differentiation program of anticancer CD8 T cells and limits the efficacy of checkpoint inhibitors
Francesca Simoncello, Giulia Maria Piperno, Nicoletta Caronni, et al.
OncoImmunology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 36
Single‐cell atlas reveals a distinct immune profile fostered by T cell‐B cell crosstalk in triple negative breast cancer
Shuning Ding, Q. L. Niu, Qingchen Zhu, et al.
Cancer Communications (2023) Vol. 43, Iss. 6, pp. 661-684
Open Access | Times Cited: 22
The tumor-draining lymph node as a reservoir for systemic immune surveillance
Ines Delclaux, Katherine S. Ventre, Dennis Jones, et al.
Trends in cancer (2023) Vol. 10, Iss. 1, pp. 28-37
Open Access | Times Cited: 20
Page 1 - Next Page

Scroll to top